Literature DB >> 15052195

Early and medium-term results for repair of Ebstein anomaly.

Jonathan M Chen1, Ralph S Mosca, Karen Altmann, Beth F Printz, Kimara Targoff, Pamela A Mazzeo, Jan M Quaegebeur.   

Abstract

OBJECTIVES: We evaluated the early and medium-term single-center results for primary repair of Ebstein anomaly in both adults and children.
METHODS: The records were reviewed of patients undergoing repair of Ebstein anomaly at the Children's Hospital of New York from September 1990 to September 2002. Functional, demographic, and echocardiographic parameters were studied both preoperatively and postoperatively, along with functional status and adverse events. The repair technique involved vertical plication of the atrialized ventricle and valve leaflet reimplantation after clockwise rotation.
RESULTS: A total of 25 patients (19 children and 6 adults) underwent repair. The average age was 14.2 +/- 15.9 years, and the average follow-up was 4.1 +/- 3.4 years. Three patients required reoperation for right ventricular overload (1 child) and progressive, severe tricuspid regurgitation (2 adults); both adults received tricuspid valve replacements, one at 4 years and the other at 8 years post-repair. Three patients had radiofrequency ablation procedures performed intraoperatively. Ten patients (40%) had moderate-to-severe tricuspid regurgitation perioperatively. However, 18 children (95%) and 5 adults (83%) demonstrated significant improvement in exercise capacity late postoperatively. Two children died suddenly 11 months and 4 years after repair. DISCUSSION: Ebstein repair has good functional outcomes in children despite residual tricuspid regurgitation, likely because of reduction in right ventricular volume loading and relative annular and ventricular plasticity. Adult patients did not demonstrate the same durability of valve repair and frequently required tricuspid valve replacement. Intraoperative radiofrequency ablation represents an important adjunctive treatment for intractable arrhythmias, which may now represent relative indications for operative intervention.

Entities:  

Mesh:

Year:  2004        PMID: 15052195     DOI: 10.1016/j.jtcvs.2003.11.037

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  A novel approach incorporating sildenafil in the management of symptomatic neonates with Ebstein's anomaly.

Authors:  Phat Pham; Andrew Hoyer; Robin Shaughnessy; Yuk M Law
Journal:  Pediatr Cardiol       Date:  2006-08-01       Impact factor: 1.655

2.  Mid-term outcomes of individualized surgeries in patients with Ebstein's anomaly.

Authors:  Jiaquan Zhu; Li Zhang; Chunrong Bao; Fangjie Xu; Fangbao Ding; Ju Mei
Journal:  Heart Vessels       Date:  2019-03-08       Impact factor: 2.037

3.  Right to left shunt through interatrial septal defects in patients with congenital heart disease: results of interventional closure.

Authors:  G Agnoletti; Y Boudjemline; P Ou; D Bonnet; D Sidi
Journal:  Heart       Date:  2005-11-03       Impact factor: 5.994

Review 4.  Valvular heart disease in congenital heart disease: a narrative review.

Authors:  Joshua M Saef; Joanna Ghobrial
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

5.  Ebstein malformation of the tricuspid valve: current concepts in management and outcomes.

Authors:  Morgan L Brown; Joseph A Dearani
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-10

6.  Cone Type Repair Has Become Our First Option in the Treatment of Adult Ebstein Anomaly.

Authors:  Baburhan Ozbek; Nursen Tanrikulu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2019-07-12       Impact factor: 1.520

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.